News & Updates
Filter by Specialty:
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
21 hours ago
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
a day ago
CtDNA-guided surveillance catches postoperative CRC recurrences early for curative treatment
For patients who have undergone curative resection for nonmetastatic colorectal cancer (CRC), performing circulating tumour DNA (ctDNA) methylation analysis during surveillance facilitates earlier detection of recurrences suitable for curative therapy, according to interim data from the phase III FIND trial.
CtDNA-guided surveillance catches postoperative CRC recurrences early for curative treatment
01 Sep 2025
Statin exposure associated with longer OS in apalutamide-treated patients with advanced prostate cancer
A study using individual patient data from the SPARTAN and TITAN randomized clinical trials has found that statin exposure was associated with superior overall survival (OS) among all patients with advanced prostate cancer (PC) who were treated with apalutamide.